Monitor ATS presentations on May 17 and 20 for Phase 1 and preclinical data on IKT-001, which could serve as near-term catalysts. Enrollment updates and site activations for IMPROVE-PAH will be key indicators of clinical execution over the coming weeks.
Price Chart
Executive Summary
Inhibikase reported a Q1 2026 net loss of $0.10 per share, slightly missing the $0.09 consensus, but operating expenses were in line with expectations. The key catalyst is the execution of the Phase 3 IMPROVE-PAH study: first patient enrolled, EMA approvals in 12 EU countries under the FAST-EU initiative, and an Orphan Drug Designation submission to the FDA. The $170.4M cash position provides runway for the ongoing trial.
Key Financial Metrics
Key Facts
- Net loss per share $(0.10) vs consensus $(0.09) (miss by ~11%)
- Cash, cash equivalents and marketable securities of $170.4M as of March 31, 2026
- First patient enrolled in registrational Phase 3 IMPROVE-PAH study (IKT-001 for PAH)
- Received EMA approval for Phase 3 in 12 EU countries under FAST-EU initiative
- Orphan Drug Designation application submitted to FDA for IKT-001 in PAH
- Two presentations of IKT-001 data at ATS International Conference (May 17 & 20, 2026)
Financial Impact
Net loss increased to $16.4M from $13.7M YoY; operating cash burn was $12.1M in Q1 2026
Risk Factors
- Clinical trial enrollment delays or slower than anticipated site activations
- Cash burn rate may accelerate with global Phase 3 expansion
- No approved products; reliance on positive trial outcomes
- Regulatory uncertainties regarding ODD and future EMA/FDA approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293347 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $1.66 | awaiting T+20 | — | $1.57 (−5.42%) |
Oct 2, 2026 25d ago | Press Release | $2.00 | awaiting T+20 | — | $1.57 (−21.50%) |
Aug 11, 2026 11w ago | Press Release | $2.40 $2.33 | ▼ −2.92% | ▼ −1.02% | $1.57 (−34.58%) |
Jul 23, 2026 13w ago | 8-K | $2.33 $2.35 | ▲ +0.86% | ▼ −2.45% | $1.57 (−32.62%) |
Jul 17, 2026 14w ago | 3 | $2.23 $2.39 | ▲ +7.17% | ▲ +3.05% | $1.57 (−29.60%) |
Jul 14, 2026 15w ago | 8-K | $2.06 $2.45 | ▼ −18.93% | ▼ −16.44% | $1.57 (+23.79%) |
Jun 29, 2026 17w ago | 8-K | $1.93 $2.33 | ▲ +20.73% | ▲ +21.00% | $1.57 (−18.65%) |
May 12, 2026 24w ago | 8-K | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.57 (−17.37%) |
May 12, 2026 24w ago | Press Release | $1.90 $1.67 | ▼ −12.11% | ▼ −11.49% | $1.57 (−17.37%) |
Apr 7, 2026 29w ago | 8-K | $1.76 $1.94 | ▲ +10.23% | ▲ +0.45% | $1.57 (−10.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers